Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 7/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590604 | 0.85 | PTPN1 (0.57) | FFAR1PTPN1GRM5CES2PTGES | |
| SCHEMBL852573 | 0.83 | PTPN1 (0.52) | FFAR1PTPN1GRM5CES2PTGES | |
| SCHEMBL16803398 | 0.82 | NPSR1 (0.44) | FFAR1GRM5MEN1KMT2AALDH1A1 | |
| SCHEMBL30873473 | 0.80 | GRM5 (0.58) | FFAR1PTPN1GRM5CES2PTGES | |
| SCHEMBL4490688 | 0.79 | CES2 (0.45) | PTPN1CES2PTGDR2ALDH1A1MAOB | |
| SCHEMBL5484146 | 0.77 | FFAR1 (0.47) | FFAR1PTPN1GRM5PTGESPTGDR2 | |
| SCHEMBL8006286 | 0.77 | GRM5 (0.53) | FFAR1PTPN1GRM5CES2PTGES | |
| SCHEMBL28788065 | 0.75 | FFAR1 (0.62) | FFAR1PTPN1GRM5CES2PTGES | |
| SCHEMBL6752278 | 0.75 | FFAR1 (0.50) | FFAR1GRM5 | |
| SCHEMBL27821982 | 0.74 | PTPN1 (0.60) | FFAR1PTPN1GRM5PTGESPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2000024742-A1 | PYRAZOLOPYRIDINE AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | FFAR1 3139/4885PTPN1 1102/4885GRM5 4425/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | FFAR1 4383/4885PTPN1 987/4885GRM5 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.